Market Newsdesk

NASHVILLE, Tenn., Dec. 17, 2020 /PRNewswire/ — Tivity Health, Inc. (NASDAQ: TVTY) today announced that it will participate in the virtual 39^th Annual J.P. Morgan Healthcare Conference, which will include a presentation by Richard Ashworth, President & Chief Executive Officer, followed by a question and answer session including Adam Holland, Chief Financial Officer, and Tommy Lewis, Chief Operating Officer, on Thursday, January 14, 2021 at 10:50 a.m. ET. A live audio-only webcast and replay of the event will be available on the “Investors” section of the Company’s website, www.tivityhealth.com. Please go to the site at least 15 minutes prior to the discussion to download and install any necessary audio software.

About Tivity Health, Inc.
Tivity Health, Inc^® (Nasdaq: TVTY) is a leading provider of healthy life-changing solutions, including SilverSneakers^®, Prime^® Fitness WholeHealth Living^® and Wisely Well™. We are actively addressing the social determinants of health, defined as the conditions in which we work, live and play. From improving health outcomes to reversing the narrative on inactivity, food insecurity, and social isolation and loneliness, we are making a difference and are transforming the way we do health. Learn more at TivityHealth.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/tivity-health-to-present-at-the-39th-annual-jp-morgan-healthcare-conference-301194898.html

SOURCE Tivity Health

DALLAS, Dec. 17, 2020 /PRNewswire/ — Crossroads Systems, Inc. (OTCQB: CRSS) (“Crossroads” or the “Company”), a holding company focused on investing in businesses that promote economic vitality and community development, through its wholly owned subsidiary Capital Plus Financial (“CPF”), today published its 2020 Social Impact Report as part of its ongoing impact measurement process and stakeholder sentiment analysis.

The 2020 Social Impact Report highlights the Company’s key advancements in impact management as well as meaningful initiatives underway. Key findings and conclusions of the report include:

• 98.4% of borrowers kept their homes during the pandemic;
• 78% of CPF borrowers were first time homebuyers;
• 25% to 35% of loans originated were to female borrowers;
• 97% retention across the CPF portfolio;
• Crossroads invested $19.4 million in improving homes and neighborhoods across the state, providing affordable homes for 156 families in San Antonio, Houston, Fort Worth and Dallas.

The 2020 Social Impact Report can be found on the Company’s website here.

Earlier this month, Crossroads CEO Eric Donnelly was featured in the Silicon Valley Business Journal, where he called for urgent bipartisan coordination to provide necessary financial support for vulnerable small businesses during the pandemic. The complete article can be viewed here.

“This year’s social impact report validates CPF’s mission to remove barriers and catalyze housing affordability, providing physical and mental stability, improved finances and reduced health problems in the process,” said Crossroads CEO Eric Donnelly. “While it is clear that our borrowers have faced hardships this year as a result of the pandemic, it is also apparent that institutions like ours have played a significant role in promoting housing security and supporting key stakeholders at all levels. We see our social impact as an equally important metric for our double bottom line business and for the investors who place their trust and capital in our vision. The key findings from the report as well as the widespread economic instability the country has experienced this year tell us that many of the communities we interact with are still in need of our support, and we stand ready to assist them.”

About Crossroads Systems
Crossroads Systems, Inc. (OTCQB: CRSS) is a holding company focused on investing in businesses that promote economic vitality and community development. Crossroads’ subsidiary, Capital Plus Financial (CPF), is a certified Community Development Financial Institution (CDFI) and certified B- Corp, which supports Hispanic homeownership with a long term, fixed-rate single-family mortgage product.

Important Cautions Regarding Forward-Looking Statements

This press release includes forward-looking statements that relate to the business and expected future events or future performance of Crossroads Systems, Inc. and Capital Plus Financial and involve known and unknown risks, uncertainties and other factors that may cause its actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “targets,” “likely,” “will,” “would,” “could,” and similar expressions or phrases identify forward-looking statements. Forward-looking statements include, but are not limited to, statements about Crossroads Systems’ and Capital Plus Financial’s ability to implement their business strategy, and their ability to achieve or maintain profitability. The future performance of Crossroads Systems and Capital Plus Financial may be adversely affected by the following risks and uncertainties: economic changes affecting homeownership in the geographies where Capital Plus Financial conducts business, developments in lending markets that may not align with Capital Plus Financial’s expectations and that may affect Capital Plus Financial’s plans to grow its portfolio, variations in quarterly results, developments in litigation to which we may be a party, technological change in the industry, future capital requirements, regulatory actions or delays and other factors that may cause actual results to be materially different from those described or anticipated by these forward-looking statements. For a more detailed discussion of these factors and risks, investors should review Crossroads Systems’ annual and quarterly reports. Forward-looking statements in this press release are based on management’s beliefs and opinions at the time the statements are made. All forward-looking statements are qualified in their entirety by this cautionary statement, and Crossroads Systems undertakes no duty to update this information to reflect future events, information or circumstances.

©2020 Crossroads Systems, Inc., Crossroads and Crossroads Systems are registered trademarks of Crossroads Systems, Inc. All trademarks are the property of their respective owners.

Company Contact:
Crossroads Systems
[email protected] 

Investor Relations Contact:
Gateway Investor Relations
Matt Glover and Tom Colton
[email protected]
(949) 574-3860

View original content to download multimedia:http://www.prnewswire.com/news-releases/capital-plus-financial-releases-2020-social-impact-report-301194983.html

SOURCE Crossroads Systems; Capital Plus Financial

WINNIPEG, MB, Dec. 17, 2020 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company“) (TSXV: MPH) (OTC: MCUJF), a cardiovascular pharmaceutical company, today announced that, through its wholly-owned U.S. subsidiary, Medicure Pharma Inc., it entered into a definitive agreement on December 15, 2020, to acquire 100% of Marley Drug, Inc (“Marley“), a leading specialty pharmacy serving more than 30,000 customers across the United States, from an arms-length third-party, for an upfront payment on closing of USD $6.3 million, subject to certain holdbacks, as well as additional payments based on future performance of Marley.  Marley generated unaudited revenue and EBITDA of approximately USD $7.0 million and over USD $1.7 million for the 12-month period ended October 31, 2020, respectively. 

Marley provides excellent customer service, cost competitive medications, immediate direct to patient delivery, and is licensed in all 50 states, Washington D.C. and Puerto Rico. Its advanced operating systems include automated pill dispensing, an extended supply generic drug program, and an effective customer communication system. Marley has been successful in marketing directly to customers, providing access to medications without the need for insurance, and building a nationwide customer base.

“This transaction marks the start of an exciting new chapter for our company,” said Albert D. Friesen, PhD, Chief Executive Officer of Medicure and Chair of its Board of Directors. “We look forward to welcoming the Marley specialty pharmacy team and dedicated customers and physicians.  The combined business will be well positioned to strengthen our existing national platforms, accelerate growth of Medicure’s primary care drug, ZYPITAMAG^® (pitavastatin) tablets, realize material synergies and generate substantial shareholder value.” The Company remains focused on the sale and commercial development of its existing products.

Medicure intends to finance the acquisition of Marley with a term loan from a Canadian commercial bank.

About Medicure Inc.
Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT^® (tirofiban hydrochloride) injection and ZYPITAMAG^® (pitavastatin) tablets in the United States, where they are sold through the Company’s U.S. subsidiary, Medicure Pharma Inc. For more information on Medicure please visit www.medicure.com. For additional information about ZYPITAMAG^®, refer to the full Prescribing Information.

About Marley
Independently owned, Marley was established in 2003 by Dr. David Marley, PharmD to offer accessible, cost effective and high-quality pharmacy services to employers and other health care consumers in North Carolina. In 2011, Marley expanded its reach, serving all 50 states and Washington D.C. with their Extended Supply mail order drug program. Marley is committed to improving the health status of their patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. For more information visit www.marleydrug.com. To learn more about The Extended Supply Generic Drug Program call 800.286.6781 or email [email protected].

To be added to Medicure’s e-mail list, please visit:        

http://medicure.mediaroom.com/alerts

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Information: Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words “believes”, “may”, “plans”, “will”, “estimates”, “continues”, “anticipates”, “intends”, “expects” and similar expressions, may constitute “forward-looking information” within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as “forward-looking statements”). Forward-looking statements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company’s ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company’s future product revenues, expected results, including revenue and growth from Marley, expected future growth in revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company’s products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company’s revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company’s research and development projects; the availability of financing for the Company’s commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company’s other filings with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the “Risk Factors” section of its Form 20F for the year ended December 31, 2019.

View original content:http://www.prnewswire.com/news-releases/medicure-enters-the-us-online-pharmacy-world-with-acquisition-of-marley-drug-301194963.html

SOURCE Medicure Inc.

SEATTLE, Dec. 17, 2020 /PRNewswire/ — (NASDAQ: RDFN) — The national median home price rose 14.0% year over year to $335,519 in November, according to a new report from Redfin (www.redfin.com), the technology-powered real estate brokerage. This marks the second-largest annual increase since at least 2012, bested only by a 14.5% gain in July 2013. These near-record gains are fueled by an extreme imbalance between homebuying demand and the supply of homes for sale. Closed home sales surged 23% from a year earlier, and pending sales were up 37%, while new listings were up just 8%.

The housing market set multiple records in November for time on market, the share of homes sold above list price and the number of homes for sale. The rate of home price and sales growth are also both near their all-time highs, suggesting that November may be the hottest housing market on record.

“Neither the election nor the Thanksgiving holiday weekend curbed homebuyers’ appetite in November,” said Redfin chief economist Daryl Fairweather. “I personally bought a home last month because I knew if I didn’t seal the deal by then, I would have to wait until January for more new listings to hit the market to find one that checked all of my boxes. Plus, there is no guarantee mortgage rates will stay this low for much longer. And like most buyers this time of year, once I had it in my head that it was time to move, I wanted to be settled in my new home in time for the holidays.”

Median home prices increased in each of the 85 largest metro areas Redfin tracks. The smallest price gains compared to a year earlier were in San Francisco (+1.8%), while the largest price increases were in Bridgeport, CT (+22%), Newark, NJ (+22%) and Memphis, TN (+20%). Nationally, home price increases leveled off in November close to the all-time high.

This is the second month in a row that the Bridgeport and Newark areas have seen the largest price gains in the nation as they continue to see an influx of newly work-from-home buyers moving from New York City in search of more space.

Home sales were up 23% in November from a year earlier on a seasonally-adjusted basis, down slightly from the record high of 25% set in October.

The number of homes sold in November was up from a year earlier in all but one of the 85 largest metro areas Redfin tracks. The largest gains in sales were in Bridgeport, CT (+65%), Lake County, IL (+45%) and Elgin, IL (+44%). The only market that saw a decrease in the number of homes sold was Honolulu (-0.8%).

Active listings—the count of all homes that were for sale at any time during the month—fell 23% year over year to their lowest level on record in November, the 16th-straight month of declines.

Only two of the 85 largest metros tracked by Redfin posted a year-over-year increase in the count of seasonally-adjusted active listings of homes for sale: San Francisco (+72%) and New York City (+32%). The number of homes for sale continued to build up in these markets as growth in new listings (53% and 37% year over year, respectively) dwarfs increases in home sales (+23% and +21%).

Compared to a year ago, the biggest declines in active housing supply in November were in Kansas City, MO (-50%), Salt Lake City (-54%) and Elgin, IL (+45%).

The number of new listings of homes for sale increased 8% in November from a year earlier, a slight dip from the seven-year high in October. Increases in new listings are still being heavily outpaced by increases in pending sales, which were up 37% year over year in November.

Measures of competition such as time on market and the share of homes sold above list price hit new records in November as they continued to run against the typical seasonal trend. The typical home that sold in November went under contract in 27 days—18 days less than a year earlier—a new all-time low since the beginning of Redfin’s data in 2012.

Typically during the last few months of the year, homes spend more time on the market and the share of homes that sell above list price declines. This year, the ongoing pandemic and recession has thrown the housing market into disarray, completely upending the typical seasonal trends.

In November, 35% of homes sold above list price—the highest level in Redfin’s data, which goes back through 2012—up from 21% a year earlier.

To read the full report, including charts and additional metro-level data highlights, please visit: https://www.redfin.com/news/november-housing-market-update-14-pct/.

About Redfin
Redfin (www.redfin.com) is a technology-powered residential real estate company, redefining real estate in the consumer’s favor in a commission-driven industry. We do this by integrating every step of the home buying and selling process and pairing our own agents with our own technology, creating a service that is faster, better and costs less. We offer brokerage, iBuying, mortgage, and title services, and we also run the country’s #1 real estate brokerage search site, offering a host of online tools to consumers, including the Redfin Estimate. We represent people buying and selling homes in over 90 markets in the United States and Canada. Since our launch in 2006, we have saved our customers over $800 million and we’ve helped them buy or sell more than 235,000 homes worth more than $115 billion.

For more information or to contact a local Redfin real estate agent, visit www.redfin.com. To learn about housing market trends and download data, visit the Redfin Data Center. To be added to Redfin’s press release distribution list, email [email protected]. To view Redfin’s press center, click here.

View original content to download multimedia:http://www.prnewswire.com/news-releases/homes-sold-in-november-went-off-market-at-the-fastest-pace-in-at-least-8-years-301194984.html

SOURCE Redfin

CAMBRIDGE, Mass., Dec. 17, 2020 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for AYVAKIT™ (avapritinib) for the treatment of adult patients with advanced systemic mastocytosis (SM). AYVAKIT is a potent and selective inhibitor of D816V mutant KIT, the primary driver of SM, and is being developed to treat advanced and non-advanced forms of the disease.

Blueprint Medicines requested priority review for this application, which, if granted, could result in a six-month review process. The FDA has a 60-day filing review period to determine whether the sNDA is complete and acceptable for filing. The FDA granted breakthrough therapy designation to AYVAKIT for the treatment of advanced SM, including the subtypes of aggressive SM, SM with an associated hematological neoplasm and mast cell leukemia.

“Today’s submission is an important step toward our goal of bringing AYVAKIT to patients with advanced systemic mastocytosis, a debilitating and life-threatening rare disease,” said Fouad Namouni, M.D., President, Research & Development. “Our application is based on an unprecedented clinical dataset in this disease, which showed that patients receiving AYVAKIT had high overall response and complete remission rates, with prolonged survival, and the treatment was generally well-tolerated. We look forward to working closely with the FDA during the review, as we seek to introduce the first precision therapy targeting the underlying cause of systemic mastocytosis.”

About SM

SM is a rare disease driven by the KIT D816V mutation. Uncontrolled proliferation and activation of mast cells result in chronic, severe and often unpredictable symptoms for patients across the spectrum of SM. The vast majority of those affected have non-advanced (indolent or smoldering) SM, with debilitating symptoms that lead to a profound, negative impact on quality of life. A minority of patients have advanced SM, which encompasses a group of high-risk SM subtypes including aggressive SM, SM with an associated hematological neoplasm and mast cell leukemia. In addition to mast cell activation symptoms, advanced SM is associated with organ damage due to mast cell infiltration and poor overall survival.

Debilitating symptoms, including anaphylaxis, maculopapular rash, pruritis, diarrhea, brain fog, fatigue and bone pain, often persist across all forms of SM despite treatment with a number of symptomatic therapies. Patients often live in fear of severe, unexpected symptoms, have limited ability to work or perform daily activities, or isolate themselves to protect against unpredictable triggers. Currently, there are no approved therapies for the treatment of SM that selectively inhibit D816V mutant KIT.

About AYVAKIT (avapritinib)

AYVAKIT (avapritinib) is a kinase inhibitor approved by the FDA for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. For more information, visit www.AYVAKIT.com. This medicine is approved in Europe under the brand name AYVAKYT® for the treatment of adults with unresectable or metastatic GIST harboring the PDGFRA D842V mutation.

AYVAKIT/AYVAKYT is not approved for the treatment of any other indication, including SM, in the U.S. by the FDA or in Europe by the European Commission, or for any indication in any other jurisdiction by any other health authority.

Blueprint Medicines is developing AYVAKIT globally for the treatment of advanced and indolent SM.

Blueprint Medicines has an exclusive collaboration and license agreement with CStone Pharmaceuticals for the development and commercialization of AYVAKIT in Mainland China, Hong Kong, Macau and Taiwan. Blueprint Medicines retains development and commercial rights for AYVAKIT in the rest of the world.

About Blueprint Medicines

Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and development of new treatments and increases the likelihood of clinical success. We have two approved precision therapies and are currently advancing multiple investigational medicines in clinical and pre-clinical development, along with a number of earlier-stage research programs. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans and timelines for the development of AYVAKIT for advanced and non-advanced SM; plans and timelines for commercializing AYVAKIT for advanced SM, if approved; the potential benefits of Blueprint Medicines’ current and future approved drugs or drug candidates in treating patients, including expectations regarding the potential of AYVAKIT for the treatment of patients with SM; and Blueprint Medicines’ strategy, goals and anticipated milestones, business plans and focus. The words “aim,” “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the impact of the COVID-19 pandemic to Blueprint Medicines’ business, operations, strategy, goals and anticipated milestones, including Blueprint Medicines’ ongoing and planned research and discovery activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Blueprint Medicines’ ability and plans in continuing to establish and maintain a commercial infrastructure, and successfully launching, marketing and selling current or future approved products; Blueprint Medicines’ ability to successfully expand the approved indications for AYVAKIT/AYVAKYT and GAVRETO™ (pralsetinib) or obtain marketing approval for AYVAKIT/AYVAKYT and GAVRETO in additional geographies in the future; the delay of any current or planned clinical trials or the development of Blueprint Medicines’ current or future drug candidates; Blueprint Medicines’ advancement of multiple early-stage efforts; Blueprint Medicines’ ability to successfully demonstrate the safety and efficacy of its drug candidates and gain approval of its drug candidates on a timely basis, if at all; the pre-clinical and clinical results for Blueprint Medicines’ drug candidates, which may not support further development of such drug candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials; Blueprint Medicines’ ability to obtain, maintain and enforce patent and other intellectual property protection for AYVAKIT/AYVAKYT, GAVRETO or any drug candidates it is developing; Blueprint Medicines’ ability to develop and commercialize companion diagnostic tests for AYVAKIT/AYVAKYT, GAVRETO or any of its current and future drug candidates; and the success of Blueprint Medicines’ current and future collaborations, partnerships or licensing arrangements. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Blueprint Medicines’ filings with the Securities and Exchange Commission (SEC), including Blueprint Medicines’ most recent Annual Report on Form 10-K, as supplemented by its most recent Quarterly Report on Form 10-Q and any other filings that Blueprint Medicines has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Blueprint Medicines’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Blueprint Medicines explicitly disclaims any obligation to update any forward-looking statements.

Trademarks 

Blueprint Medicines, AYVAKIT, AYVAKYT, GAVRETO and associated logos are trademarks of Blueprint Medicines Corporation. 

View original content to download multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-submits-supplemental-new-drug-application-to-fda-for-ayvakit-avapritinib-for-the-treatment-of-advanced-systemic-mastocytosis-301194719.html

SOURCE Blueprint Medicines Corporation

PALM BEACH GARDENS, Fla., Dec. 17, 2020 /PRNewswire/ — Carrier Global Corporation’s (NYSE: CARR) BluEdge service platform continues to expand its reach with 1,000 signed service agreements in just six months and expanded geographic reach. The global, best-in-class service program that was originally launched in North America and Asia, is now available to Commercial HVAC customers in the Middle East and Europe. Through a deep understanding of customer needs and investments in cutting edge digital tools, BluEdge can help customers achieve enhanced equipment efficiency and performance – key components of Carrier’s Healthy Buildings Program and Healthy, Safe, Sustainable Cold Chain Program. Carrier Global Corporation is a leading global provider of healthy, safe and sustainable building and cold chain solutions.

“We are thrilled with the positive customer response to our BluEdge platform and honored to hit this milestone so quickly,” said Ajay Agrawal, Senior Vice President, Strategy & Services, Carrier. “The BluEdge tiered offerings are resonating with the customers since we designed them to meet their specific needs. BluEdge helps customers achieve optimal equipment performance and act on data-driven insights, which is becoming increasingly important as we look to the future. As a result, we are on track to hit a 30% conversion rate in Commercial HVAC this year.” 

The Carrier team continues to innovate new ways for BluEdge to reach customers and improve outcomes. Carrier Commercial Refrigeration, in partnership with EcoEnergy Insights, also a Carrier company, recently completed a successful pilot of its new Condition Based Maintenance (CBM) program that uses predictive AI-driven algorithms to proactively service refrigeration equipment in retail food stores. CBM is aimed at improving overall customer satisfaction levels by reducing equipment downtime. The pilot resulted in a 30% reduction in alarms related to equipment issues or breakdowns and a double-digit improvement in equipment uptime. Based on the pilot program’s results, Carrier plans to expand this program to 10,000 stores across Europe by the end of 2023.

Central to BluEdge is a tiered-service model that provides customers with a range of dynamic options to meet the needs of their businesses. These tiers of service include:

• Core. Customers benefit from as-needed expert service to help ensure peak equipment performance and longevity.
• Enhance. Customers can customize on-demand and value-added services, such as multi-year service agreements, preventive maintenance and remote monitoring.
• Elite. Customers who want complete peace of mind can choose this comprehensive solution that can help optimize performance, and help maximize uptime and minimize cost.

For more information on the BluEdge service platform, visit www.corporate.carrier.com/BluEdge.

About Carrier

As the leading global provider of healthy, safe and sustainable building and cold chain solutions, Carrier Global Corporation is committed to making the world safer, sustainable and more comfortable for generations to come. From the beginning, we’ve led in inventing new technologies and entirely new industries. Today, we continue to lead because we have a world-class, diverse workforce that puts the customer at the center of everything we do. For more information, visit www.Corporate.Carrier.com or follow us on social media at @Carrier.

CARR-IR

View original content to download multimedia:http://www.prnewswire.com/news-releases/carrier-secures-1-000-bluedge-service-contracts-in-first-six-months-expands-geographic-coverage-301194979.html

SOURCE Carrier Global Corporation

                                                                                              Shares Outstanding: 264,429,288
Trading Symbols: TSX: GGD
OTCQX: GLGDF

­­­­­­­­­­­­­­­­HALIFAX, NS, Dec. 17, 2020 /PRNewswire/ – GoGold Resources Inc. (TSX: GGD) (OTCQX: GLGDF) (“GoGold”, “the Company”) is pleased to announce the release of financial results for the quarter and year ending September 30, 2020 with record annual revenue of $39.5 million (all amounts are in U.S. dollars) from the sale of 2.2 million silver equivalent ounces which provided cash flow from operations before working capital changes of $8.7 million.

“Parral had a record production year and a record quarter which generated $6.5 million US of cash flow, paying for all of our exploration and general and administrative costs.  We have one of the largest drilling programs in Mexico and we are currently self funding from operations at Parral.  Parral had an excellent year which resulted in a reversal of a previously recorded impairment of $41.1 million, which really reflects on how strongly that asset is performing now,” Brad Langille, President and CEO stated.  “With our $52.7 million US cash balance and the cash flow from our Parral operation, we are well positioned to continue the rapid advancement of the Los Ricos district.”

Financial Highlights for the year ending September 30, 2020:

• Cash flow from operations before working capital changes of $8.7 million, including free cash flow from Parral of $12.6 million
• Net income of $43.1 million ($0.21 per share)
• Record revenue of $39.5 million, an increase of 46%, on the sale of 2.2 million silver equivalent ounces at a realized price per ounce of $18.00
• Cash of $52.7 million
• All in sustaining costs of $14.82 per silver equivalent ounce
• Cash costs of $12.24 per silver equivalent ounce

At Parral, the project generated $39.5 million on sales of 2.2 million silver equivalent ounces for the year ended September 30, 2020, which is an increase of 46% compared to the prior year’s $27.0 million, while costs were similar.  All in sustaining costs (“AISC”) were $14.72 per ounce and cash costs were $12.24 in 2020, compared to AISC of $14.82 and cash costs of $11.80 in 2019. 

With the strength of Parral’s operations in the year, at September 30 the Company recorded a non-cash reversal of impairment of $41.1 million, which was recorded through net income.  The Company determined that increased positive cash flows, operational performance, and an increase in metal prices at the Parral project constituted indicators that a previously recorded impairment of $48.2 million on September 30, 2018 at Parral no longer existed, with the difference attributed to depreciation which would have been recorded had the initial impairment not been recorded.

At Los Ricos, the Company capitalized $8.3 million to the projects for drilling, exploration and consulting for the year ending September 30, 2020, compared to $1.8 million in the prior year.   This included $5.5 million at Los Ricos South and $2.8 million at Los Ricos North.  During the year, GoGold drilled 36,100 metres, released assay results for 194 drill holes, and released an initial Mineral Resource estimate at Los Ricos South.  The Measured & Indicated Mineral Resource at Los Ricos South includes 63.7 million ounces silver equivalent (“AgEq”) grading 199 g/t AgEq contained in 10.0 million tonnes (“Mt”), with an Inferred Resource of of 19.9 million ounces AgEq grading 190 g/t AgEq contained in 3.3 Mt.

Financial Highlights for the quarter ending September 30, 2020:

• Cash flow from operations before changes in working capital of $5.5 million, including free cash flow from Parral of $6.5 million
• Net income of $44.6 million ($0.21 per share)
• Revenue of $13.8 million on the sale of 605,723 silver equivalent ounces at a realized price per ounce of $22.71
• All in sustaining costs of $14.31 per silver equivalent ounce
• Cash costs of $11.97 per silver equivalent ounce

Following are tables showing summarized financial information and key performance indicators:

 

 

This news release should be read in conjunction with the consolidated financial statements for the year ended September 30, 2020, notes to the financial statements, and management’s discussion and analysis for the year ended September 30, 2020, which have been filed on SEDAR and are available on the Company’s website. 

Technical information contained in this news release with respect to GoGold has been reviewed and approved by Mr. Bob Harris, P.Eng., who is a qualified person for the purposes of NI 43-101.

CAUTIONARY STATEMENT:

The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and may not be offered or sold within the United States or to, or for the benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any of GoGold’s securities in the United States.

This news release may contain “forward-looking information” as defined in applicable Canadian securities legislation. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Parral tailings project, the Los Ricos project, future operating margins, future production and processing, and future plans and objectives of GoGold, constitute forward looking information that involve various risks and uncertainties. Forward-looking information is based on a number of factors and assumptions which have been used to develop such information but which may prove to be incorrect, including, but not limited to, assumptions in connection with the continuance of GoGold and its subsidiaries as a going concern, general economic and market conditions, mineral prices, the accuracy of mineral resource estimates, and the performance of the Parral project There can be no assurance that such information will prove to be accurate and actual results and future events could differ materially from those anticipated in such forward-looking information.

Important factors that could cause actual results to differ materially from GoGold’s expectations include exploration and development risks associated with the GoGold’s projects, the failure to establish estimated mineral resources or mineral reserves, volatility of commodity prices, variations of recovery rates, the effects of the global COVID-19 pandemic, and global economic conditions. For additional information with respect to risk factors applicable to GoGold, reference should be made to GoGold’s continuous disclosure materials filed from time to time with securities regulators, including, but not limited to, GoGold’s Annual Information Form. The forward-looking information contained in this release is made as of the date of this release.

Cautionary non-GAAP Measures and Additional GAAP Measures

Note that for purposes of this section, GAAP refers to IFRS. The Company believes that investors use certain non-GAAP and additional GAAP measures as indicators to assess mining companies. They are intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared with GAAP. Non-GAAP and additional GAAP measures do not have a standardized meaning prescribed under IFRS and therefore may not be comparable to similar measures presented by other companies.

Additional GAAP measures that are presented on the face of the Company’s consolidated statements of comprehensive income include “Operating income (loss)”. These measures are intended to provide an indication of the Company’s mine and operating performance. “Cash flow from operating activities before changes in non-cash working capital” is a non-GAAP performance measure that could provide an indication of the Company’s ability to generate cash flows from operations, and is calculated by adding back the change in non-cash working capital to “Net cash used in operating activities” as presented on the Company’s consolidated statements of cash flows. Per ounce measures are calculated by dividing the relevant mining and processing costs and total costs by the tonnes of ore processed in the period. “Cash costs per ounce” and “all-in sustaining costs per ounce” as used in this analysis are non-GAAP terms typically used by mining companies to assess the level of gross margin available to the Company by subtracting these costs from the unit price realized during the period. These non-GAAP terms are also used to assess the ability of a mining company to generate cash flow from operations. There may be some variation in the method of computation of these metrics as determined by the Company compared with other mining companies. In this context, “cash costs per ounce” reflects the cash operating costs allocated from in-process and dore inventory associated with ounces of silver and gold sold in the period. “Cash costs per ounce” may vary from one period to another due to operating efficiencies, grade of material processed and silver/gold recovery rates in the period. “All-in sustaining costs per ounce” include total cash costs, exploration, corporate and administrative, share based compensation and sustaining capital costs. For a reconciliation of non-GAAP and GAAP measures, please refer to the Management Discussion and Analysis dated December 16, 2020, for the year ended September 30, 2020, as presented on SEDAR.

View original content:http://www.prnewswire.com/news-releases/gogold-reports-net-income-of-43-1m-us-for-year-ending-september-30–2020–301194952.html

SOURCE GoGold Resources Inc.

ROCKVILLE, Md., Dec. 17, 2020 /PRNewswire/ — Choice Hotels International, Inc. (NYSE: CHH), one of the world’s largest lodging franchisors, is once again joining forces with Operation Homefront, a national nonprofit whose mission is to create strong, stable and secure military families. Building on the company’s ongoing support since the partnership began in 2018, Choice Hotels expects to raise over $100,000 and will donate 500 room nights to assist military families by year-end. As part of this year’s donation efforts, the company is holding a “Season of Giving” holiday drive, where members of its award-winning loyalty program, Choice Privileges, can redeem their points to help servicemembers, and Choice will make a matching donation up to $50,000.

“It’s no secret that this has been a challenging year for many around the world, but especially so for service members and their families. When the COVID-19 pandemic began, we supported Operation Homefront families by donating Choice Privileges points towards hotel rooms to help those displaced — an effort that was amplified by our incredibly generous loyalty members,” said Patrick Pacious, president and chief executive officer, Choice Hotels. “We’re doubling down now on the opportunity for Choice Privileges members to redeem their points to benefit this worthy cause by committing to match their efforts with our own $50,000 donation, which will help reunite service members with their loved ones.”

The partnership between Choice Hotels and Operation Homefront allows the leading nonprofit to continue supporting the critical financial needs of military families, including rent payments, car and home repairs, food, utility bills, grocery assistance and more. Since the beginning of the partnership, over 28 million Choice Privileges points have been donated to Operation Homefront – nearly 3,000 room nights.

–  In 2018, Choice pledged 2,000 room nights to help veterans and active duty service members connect with their families and friends throughout the year.

–  Last year, Choice and Operation Homefront launched the “Choice Salutes” campaign for Veterans Day weekend, where a portion of proceeds from hotel reservations were donated to military families. Residents of Operation Homefront’s Transitional Housing Village in Gaithersburg, Maryland were surprised with a trip to visit their families for the holidays.

–  Since the beginning of the partnership, more than 600 bicycles have been donated to Operation Homefront as part of an annual company holiday tradition, where Choice Hotels employees collect and assemble bicycles for Operation Homefront families.

To further express its appreciation for those who serve, Choice Hotels offers military benefits and features under the Choice Privileges program, including:

–  Upgraded Membership: Immediately upon registration, active duty or reserve military members and retired military, National Guard, and U.S. Coast Guard personnel will earn Lifetime Gold Elite status, which entitles members to 10% extra points on every stay and an Elite Welcome Gift upon check-in at Choice-branded hotels.

–  2,500 Choice Privileges Points: As an extra thank you, new and existing Choice Privileges members will earn 2,500 points on their next stay after completing the military registration form.

Operation Homefront has fulfilled nearly 44,000 requests for assistance since 2011, providing military families with more than $28 million in critical financial support.

“Many families across America are struggling to make ends meet and sadly, our military families have been especially hard hit and the need for our highly-valued programs is more important now than ever.  As we face a surge in requests for assistance, we are thrilled to have Choice Hotels, and their Choice Privileges members, join us as we work to help this very deserving group of fellow citizens overcome their financial hardships,” said Brig. Gen. (ret.) John I. Pray Jr., president and chief executive officer, Operation Homefront.  “We need to be there for them in their time of need for all they have done, and continue to do, for all of us in our nation’s time of need.”

Choice Hotels has a long history of enhancing the diversity of its ownership base through a one-of-a-kind emerging markets development team, which helps underrepresented individuals, including veterans, enter the rewarding business of hotel franchising. As a result of Choice Hotels’ commitment to creating a bright future for veterans, the company was recently named by Forbes as a Best Employer for Veterans. To learn more about Choice Hotels and Operation Homefront, visit ChoiceHotels.com/OperationHomefront.

About Choice Hotels

^®




Choice Hotels International, Inc. (NYSE: CHH) is one of the largest lodging franchisors in the world. With more than 7,100 hotels, representing nearly 600,000 rooms, in over 40 countries and territories as of September 30, 2020, the Choice^® family of hotel brands provide business and leisure travelers with a range of high-quality lodging options from limited service to full-service hotels in the upscale, midscale, extended-stay and economy segments. The award-winning Choice Privileges^® loyalty program offers members benefits ranging from everyday rewards to exceptional experiences. For more information, visit www.choicehotels.com.  

About Operation Homefront 

Founded in 2002, Operation Homefront is a national nonprofit organization whose mission is to build strong, stable, and secure military families so that they can thrive – not simply struggle to get by – in the communities they have worked so hard to protect. Recognized for superior performance by leading independent charity oversight groups, over 90 percent of Operation Homefront expenditures go directly to programs that support tens of thousands of military families each year. Operation Homefront provides critical financial assistance, transitional and permanent housing and family support services to prevent short-term needs from turning into chronic, long-term struggles. Thanks to the generosity of our donors and the support from thousands of volunteers, Operation Homefront proudly serves America’s military families. For more information, visit OperationHomefront.org.

 

© 2020 Choice Hotels International, Inc. All rights reserved.

View original content to download multimedia:http://www.prnewswire.com/news-releases/choice-hotels-re-enlists-with-operation-homefront-for-third-straight-year-to-support-military-families-301194917.html

SOURCE Choice Hotels International, Inc.

OMAHA, Neb., Dec. 17, 2020 /PRNewswire/ — Union Pacific Corporation (NYSE: UNP) will release fourth quarter 2020 financial and operating results on Thursday, January 21, 2021, at 8:00 a.m. ET. The company’s management team will host a conference call and live webcast at 8:45 a.m. ET.

Parties interested in participating via teleconference may dial 877-407-8293. International callers may dial 201-689-8349. A live webcast of the presentation and materials will be available in the investor relations section of Union Pacific’s website at www.up.com/investor. A replay of the audio webcast will be available shortly thereafter.

ABOUT UNION PACIFIC

Union Pacific (NYSE: UNP) delivers the goods families and businesses use every day with safe, reliable and efficient service. Operating in 23 western states, the company connects its customers and communities to the global economy. Trains are the most environmentally responsible way to move freight, helping Union Pacific protect future generations. More information about Union Pacific is available at www.up.com.

www.up.com

www.facebook.com/unionpacific

www.twitter.com/unionpacific

View original content to download multimedia:http://www.prnewswire.com/news-releases/union-pacific-corporation-announces-fourth-quarter-2020-earnings-release-date-301194914.html

SOURCE Union Pacific Corporation

VANCOUVER, BC, Dec. 17, 2020 /PRNewswire/ – Cache Exploration Inc. (the “Company” or “Cache”) (TSXV: CAY) (OTC Pinksheet: CEXPF) is pleased to announce plans for winter drilling at the Kiyuk Lake gold project, Nunavut.  Drilling is set to start in late February 2021 and will include up to 4,000m of core drilling focused on expanding gold mineralization discovered at the Rusty and Gold Point zones as well as the new discovery East Gold Point.  This will be the first drill program at Kiyuk Lake since the successful 2017 drill program.

“The 2017 drill program at Kiyuk Lake was very successful. ” stated Cache’s President and CEO Jack Bal. “The discovery of high grade gold at the Rusty Zone and new gold discoveries elsewhere on the project proved the exploration concept. We now look forward to getting back to drilling, following up on those discoveries and making new discoveries in 2021”. 

Rusty Zone
Drilling at the Rusty zone will be focused on offsetting the high-grade gold intercepts in 2017 and expanding the disseminated gold mineralization at depth and at surface to the south and east.  Drilling in 2013 and 2017 demonstrated strong continuity of breccia-hosted gold mineralization within the Rusty zone. 

Highlights from previous drilling at Rusty include:

• 8.0m at 26.4 g/t Au from 108m
• 52.4 m at 3.2 g/t Au from surface
• 35.9 m at 4.9 g/t Au from 134.1 m
• 61.5 m at 3.3 g/t Au from 159 m
• 122.0m at 1.8 g/t Au from 188m

Gold Point Zone & East Gold Point Discovery
The Gold Point zone is a high priority target located in a 24 kilometre magnetic anomaly coinciding with a polymictic conglomerate that will receive further drilling in this program.  Ground magnetics, prospecting and mapping in 2012 and 2013 identified a possible extension of Gold Point mineralization by the discovery of similar mineralization, in boulders, in the polymictic conglomerate that hosts the Gold Point zone. These extensional zones – South Gold Point and East Gold Point respectively – were further defined by ground magnetics as zones of magnetite destruction coincident with east-west structures, which are identical to those found at the Gold Point zone.  Drilling in 2017 resulted in a new discovery at East Gold Point. Drilling in 2021 will focus on expanding East Gold Point and discovery drilling at South Gold Point in addition to the expansion drilling at Gold Point. 

Previous drilling at the Gold Point zone returned:

• 63.6 m at 2.84 g/t Au from 148 m
• 12 m at 2.4 g/t Au from 120 m
• 12 m at 3.9 g/t Au from 163.5 m

East Gold Point, is located 700m to the east of the Gold Point zone. This previously untested target was defined by coincidence of magnetite destructive features observed in ground magnetic data and the presence of mineralized boulders on surface. East Gold Point represents a ‘proof of concept’ new discovery that confirms the prospective potential of structures that cross cut the polymictic conglomerate unit. Success in intercepting significant gold mineralization in the first drill hole to target the northern most extent of this structure is a positive result for further development of gold mineralization models at the Kiyuk Lake project. The strike length of the magnetite destructive features is yet to be determined and will require further ground magnetic surveying to define and constrain their extent.

Drilling at the East Gold Point returned:

• 64.0 m at 1.46 g/t Au from 35 m
• 10 m at 6.5 g/t Au from 248 m

Claim Status and Permitting
The Kiyuk Lake project is fully permitted for drilling with a Land Use Permit for exploration activities until 2024 and Water Licence supporting camp and drilling activities until 2022. 

In 2019, a survey of 25 mineral claims was completed to convert the minerals claims to mineral leases. 28 mineral leases are now held by Cache with only annual rent payments required with no minimum work commitment.

About Cache Exploration
Cache Exploration is focused on its Kiyuk Lake gold project in Nunavut. Kiyuk Lake is a true district play in a new gold camp, covering a majority proportion of the Proterozoic Kiyuk Basin. The property has seen 13,500 meters of drilling in 4 drill programs from 2008-2017.  Gold Showings occur over 15 Km in the basin. Drilling has discovered multiple gold intercepts over 1 g/t Au in five discrete mineralized zones Rusty, Gold Point, East Gold Point, Cobalt and Amundsen. Significant expansion possible with five new target areas identified and ready for drilling. Exploration at Kiyuk Lake takes place in winter-spring (February – May) and summer-fall (June-October).

Qualified Person

Chris Pennimpede, P. Geo., is a Qualified Person as defined by National Instrument 43-101, has reviewed and verified the technical mining information provided in this release.

For more information about Cache Exploration, please visit: http://www.cacheexploration.com/

On behalf of the Board of Directors.
Cache Exploration Inc.
s/Jack Bal

Jack Bal,
Chief Executive Officer

View original content to download multimedia:http://www.prnewswire.com/news-releases/cache-exploration-to-commence-drill-program-at-kiyuk-lake-gold-project-in-february-2021-301194987.html

SOURCE Cache Exploration Inc.